Volumen | 3.667 |
|
|||||
News | - |
Finanzwerte SMMT
Börsenwert | Emittierte Aktien | Float | Erlöse | Gewinn/Verlust | Ertrag je Aktie | Kurs-Gewinn-Verhältnis |
---|---|---|---|---|---|---|
5,56B | 700,84M | - | 1M | -614,93M | -0,88 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Summit Therapeutics
Datum | Zeit | Quelle | Überschrift |
---|---|---|---|
18.6.2024 | 23:14 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
17.6.2024 | 23:25 | Edgar (US Regulatory) | Form 8-K - Current report |
13.6.2024 | 20:03 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
03.6.2024 | 12:18 | Edgar (US Regulatory) | Form 8-K - Current report |
03.6.2024 | 12:05 | Edgar (US Regulatory) | Form 8-K - Current report |
03.6.2024 | 11:30 | Business Wire | Summit Raises $200 Million; Also Expands License Territories.. |
01.6.2024 | 14:00 | Business Wire | Ivonescimab Manuscript for HARMONi-A Clinical Trial Results.. |
01.6.2024 | 01:00 | Business Wire | Ivonescimab in Combination with Chemotherapy Approved in.. |
31.5.2024 | 00:00 | Business Wire | Summit Therapeutics Reports Inducement Grants Under Nasdaq.. |
30.5.2024 | 22:48 | Edgar (US Regulatory) | Form 8-K - Current report |
30.5.2024 | 20:29 | Business Wire | Ivonescimab Monotherapy Decisively Beats Pembrolizumab.. |
24.5.2024 | 14:35 | Edgar (US Regulatory) | Form 8-K - Current report |
Forum Summit Therapeutics
Keine Diskussionen Gefunden.Neuen Thread Erstellen
SMMT Historisch
Zeitraum † | Handelsbeginn | Hoch | Niedrig | VWAP | Durchsch. Volumen | Änderung | % |
---|---|---|---|---|---|---|---|
1 Woche | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
1 Monat | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
3 Monate | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
6 Monate | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
1 Jahr | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
3 Jahre | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
5 Jahre | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |